218 related articles for article (PubMed ID: 17983732)
1. Development of a twice daily dosing regimen of amoxicillin/clavulanate.
Bax R
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S118-21. PubMed ID: 17983732
[TBL] [Abstract][Full Text] [Related]
2. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
[TBL] [Abstract][Full Text] [Related]
3. Introduction: historical perspective and development of amoxicillin/clavulanate.
Geddes AM; Klugman KP; Rolinson GN
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S109-12. PubMed ID: 17900874
[TBL] [Abstract][Full Text] [Related]
4. The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections.
Ball P
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S113-7. PubMed ID: 17997283
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
Balgos AA; Rodriguez-Gomez G; Nasnas R; Mahasur AA; Margono BP; Tinoco-Favila JC; Sansores-Martinez RH; Hassan M; Beppo O; Wongsa A; Cukier A; Vargas F
Int J Clin Pract; 1999; 53(5):325-30. PubMed ID: 10695094
[TBL] [Abstract][Full Text] [Related]
7. The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
File TM
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S131-4. PubMed ID: 18029151
[TBL] [Abstract][Full Text] [Related]
8. Conclusions: the future of antimicrobial therapy - Augmentin and beyond.
Ball P
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S139-41. PubMed ID: 18029150
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of amoxicillin-clavulanic acid 1000/125mg twice daily extended release (XR) tablet for the treatment of bacterial community-acquired pneumonia in adults.
Prabhudesai PP; Jain S; Keshvani A; Kulkarni KP
J Indian Med Assoc; 2011 Feb; 109(2):124-7. PubMed ID: 21888181
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of pediatric patients with acute bacterial rhinosinusitis in Thailand: a randomized, investigator-blinded, controlled trial.
Poachanukoon O; Kitcharoensakkul M
Clin Ther; 2008 Oct; 30(10):1870-9. PubMed ID: 19014842
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience.
Rakkar S; Roberts K; Towe BF; Flores SM; Heyd A; Warner J
Int J Clin Pract; 2001 Jun; 55(5):309-15. PubMed ID: 11452678
[TBL] [Abstract][Full Text] [Related]
12. A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media.
Noel GJ; Blumer JL; Pichichero ME; Hedrick JA; Schwartz RH; Balis DA; Melkote R; Bagchi P; Arguedas A
Pediatr Infect Dis J; 2008 Jun; 27(6):483-9. PubMed ID: 18449063
[TBL] [Abstract][Full Text] [Related]
13. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.
Jacobs MR
Expert Rev Anti Infect Ther; 2005 Jun; 3(3):353-60. PubMed ID: 15954852
[TBL] [Abstract][Full Text] [Related]
14. The comparison of single-dose ceftriaxone, five-day azithromycin, and ten-day amoxicillin/clavulanate for the treatment of children with acute otitis media.
Biner B; Celtik C; Oner N; Küçükuğurluoğlu Y; Güzel A; Yildirim C; Adali MK
Turk J Pediatr; 2007; 49(4):390-6. PubMed ID: 18246740
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.
Paris R; Confalonieri M; Dal Negro R; Ligia GP; Mos L; Todisco T; Rastelli V; Perna G; Cepparulo M
J Chemother; 2008 Feb; 20(1):77-86. PubMed ID: 18343748
[TBL] [Abstract][Full Text] [Related]
16. Combating resistance: application of the emerging science of pharmacokinetics and pharmacodynamics.
Jacobs MR
Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S122-6. PubMed ID: 17936592
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of twice-daily amoxycillin/clavulanate ('Augmentin-Duo' 400/57) in mild to moderate lower respiratory tract infection in children.
Cook RC; Zachariah J; Cree F; Harrison HE
Br J Clin Pract; 1996; 50(3):125-8. PubMed ID: 8733329
[TBL] [Abstract][Full Text] [Related]
18. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis.
Arrieta JR; Galgano AS; Sakano E; Fonseca X; Amábile-Cuevas CF; Hernández-Oliva G; Vivar R; González G; Torres A;
Am J Otolaryngol; 2007; 28(2):78-82. PubMed ID: 17362810
[TBL] [Abstract][Full Text] [Related]
19. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily].
Jehl F; Klossek JM; Peynegre R; Serrano E; Castillo L; Bobin S; Desprez D; Renault C; Neel V; Rouffiac E; Borie C
Presse Med; 2002 Oct; 31(34):1596-603. PubMed ID: 12426976
[TBL] [Abstract][Full Text] [Related]
20. A world-wide summary of clinical experience with augmentin.
Croydon P
J Chemother; 1989 Jul; 1(4 Suppl):644-5. PubMed ID: 16312572
[No Abstract] [Full Text] [Related]
[Next] [New Search]
